First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.

Date publication

mai 2021

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34031056

Résumé

Double inhibition of EGFR using a tyrosine kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for non-small-cell lung cancer (NSCLC). We assessed efficacy and toxicity of afatinib+cetuximab versus afatinib, in first-line treatment of advanced -mutant NSCLC.

Référence

Clin Cancer Res. 2021 May 24;: